{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T13:47:50Z","timestamp":1778075270213,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007210","name":"Varian Medical Systems","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007210","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019711","name":"London Health Sciences Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012118","name":"Ontario Institute for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012118","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004203","name":"Ontario Institute for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004203","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ijrobp.2025.09.026","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:30:51Z","timestamp":1759210251000},"page":"1340-1349","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Dosimetric Outcomes for Stereotactic Radiation Therapy in Early-Stage Non-Small Cell Lung Cancer and Interstitial Lung Disease: A Secondary Analysis of the ASPIRE-ILD Trial"],"prefix":"10.1016","volume":"124","author":[{"given":"Alexa","family":"Dang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Palma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pencilla","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Warner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Houda","family":"Bahig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander V.","family":"Louie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Harrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meredith E.","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brock J.","family":"Debenham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Ryerson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stewart","family":"Gaede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.09.026_bib0001","first-page":"13","article-title":"Stereotactic body radiation therapy (SBRT) in the management of non-small-cell lung cancer: Clinical impact and patient perspectives","volume":"9","author":"Donovan","year":"2018","journal-title":"Lung Cancer (Auckl)"},{"key":"10.1016\/j.ijrobp.2025.09.026_bib0002","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/JTO.0000000000000359","article-title":"Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival after stereotactic body radiation therapy for lung cancer","volume":"10","author":"Ueki","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.026_bib0003","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ijrobp.2017.03.010","article-title":"Treatment-related toxicity in patients with early-stage non-small cell lung cancer and coexisting interstitial lung disease: A systematic review","volume":"98","author":"Chen","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.09.026_bib0004","first-page":"e37","article-title":"Treatment toxicity and outcomes following definitive radiotherapy for patients with early-stage non-small cell lung cancers and pre-existing interstitial lung disease \u2013 A systematic review","volume":"120","author":"Li","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.ijrobp.2025.09.026_bib0005","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/jamaoncol.2023.7269","article-title":"Stereotactic radiation therapy in early Non\u2013Small cell lung cancer and interstitial lung disease: A nonrandomized clinical trial","volume":"10","author":"Palma","year":"2024","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.ijrobp.2025.09.026_bib0006","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1186\/s12885-019-6392-8","article-title":"Assessment of precision irradiation in early non-small cell lung cancer and interstitial lung disease (ASPIRE-ILD): study protocol for a phase II trial","volume":"19","author":"Palma","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2025.09.026_bib0007","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.18.00622","article-title":"Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non\u2013small-cell lung cancer: NRG oncology\/RTOG 0813 trial","volume":"37","author":"Bezjak","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.026_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1748-717X-4-1","article-title":"Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: Report from the Quality Assurance Working Party of the randomised phase III ROSEL study","volume":"4","author":"Hurkmans","year":"2009","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.026_bib0009","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3857\/roj.2017.00066","article-title":"Predictive factors of symptomatic radiation pneumonitis in primary and metastatic lung tumors treated with stereotactic ablative body radiotherapy","volume":"35","author":"Kim","year":"2017","journal-title":"Radiat Oncol J"},{"key":"10.1016\/j.ijrobp.2025.09.026_bib0010","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.ijrobp.2016.03.024","article-title":"Simple factors associated with radiation-induced lung toxicity after stereotactic body radiation therapy of the thorax: A pooled analysis of 88 studies","volume":"95","author":"Zhao","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.09.026_bib0011","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13014-020-1479-6","article-title":"Correlation of dosimetric factors with the development of symptomatic radiation pneumonitis in stereotactic body radiotherapy","volume":"15","author":"Ryckman","year":"2020","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.026_bib0012","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijrobp.2018.11.028","article-title":"Organs at risk considerations for thoracic stereotactic body radiation therapy: What is safe for lung parenchyma?","volume":"110","author":"Kong","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.09.026_bib0013","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3390\/cancers10080257","article-title":"Stereotactic body radiation therapy for patients with pulmonary interstitial change: High incidence of fatal radiation pneumonitis in a retrospective multi-institutional study","volume":"10","author":"Onishi","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijrobp.2025.09.026_bib0014","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s40001-024-01673-2","article-title":"Factors influencing long-term outcomes in fibrotic interstitial lung disease (F-ILD) diagnosed through multidisciplinary discussion (MDD): A prospective cohort study","volume":"29","author":"Liao","year":"2024","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.ijrobp.2025.09.026_bib0015","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","article-title":"Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer","volume":"24","author":"Timmerman","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.026_bib0016","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.21037\/jtd.2018.05.75","article-title":"Lung cancer and interstitial lung disease: A literature review","volume":"10","author":"Naccache","year":"2018","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ijrobp.2025.09.026_bib0017","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1007\/s10067-025-07511-y","article-title":"Computed tomography-based quantitative scoring system for rheumatoid arthritis\u2013associated interstitial lung disease: A retrospective diagnostic accuracy study for progressive fibrosis detection","volume":"44","author":"Karacao\u011flu","year":"2025","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ijrobp.2025.09.026_bib0018","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/resp.13820","article-title":"High attenuation areas in pulmonary computed tomography: Their meaning and use in interstitial lung disease","volume":"25","author":"Lau","year":"2020","journal-title":"Respirology"},{"key":"10.1016\/j.ijrobp.2025.09.026_bib0019","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.21037\/jtd.2017.08.17","article-title":"Lung densitometry: Why, how and when","volume":"9","author":"Mascalchi","year":"2017","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ijrobp.2025.09.026_bib0020","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S2213-2600(15)00096-X","article-title":"CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: A position paper from the Fleischner Society","volume":"3","author":"Hansell","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ijrobp.2025.09.026_bib0021","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1080\/0284186X.2020.1730002","article-title":"Stereotactic ablative radiotherapy in patients with early-stage non-small cell lung cancer and co-existing interstitial lung disease","volume":"59","author":"Finazzi","year":"2020","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.026_bib0022","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1513\/AnnalsATS.201808-510OC","article-title":"Outcomes of older patients with pulmonary fibrosis and non-small cell lung cancer","volume":"16","author":"Whittaker Brown","year":"2019","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.ijrobp.2025.09.026_bib0023","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report","volume":"194","author":"Collard","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijrobp.2025.09.026_bib0024","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4103\/jmp.JMP_111_19","article-title":"Dose calculation comparisons between three modern treatment planning systems","volume":"45","author":"Bosse","year":"2020","journal-title":"J Med Phys"},{"key":"10.1016\/j.ijrobp.2025.09.026_bib0025","unstructured":"Reducing respiratory symptoms of pulmonary irradiation in interstitial lung disease: A 2x2 factorial randomized phase II trial testing N-acetyl cysteine and dexamethasone. ClinicalTrials.gov identifier: NCT05986318. Updated January 27, 2025. Accessed August 2, 2024. https:\/\/clinicaltrials.gov\/study\/NCT05986318"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625062881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625062881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T13:04:33Z","timestamp":1773752673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301625062881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0360301625062881"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.09.026","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dosimetric Outcomes for Stereotactic Radiation Therapy in Early-Stage Non-Small Cell Lung Cancer and Interstitial Lung Disease: A Secondary Analysis of the ASPIRE-ILD Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.09.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}